Florida International University

FIU Digital Commons
Coronavirus Research at FIU
6-1-2021

Gut microbiota in COVID-19 treatment
Tella Sadighpour
Herbert Wertheim College of Medicine, Florida International University; American University of Antigua,
College of Medicine

Audrey Tolouian
The University of Texas at El Paso School of Nursing

Follow this and additional works at: https://digitalcommons.fiu.edu/covid-19_research

Recommended Citation
Sadighpour, Tella and Tolouian, Audrey, "Gut microbiota in COVID-19 treatment" (2021). Coronavirus
Research at FIU. 90.
https://digitalcommons.fiu.edu/covid-19_research/90

This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in
Coronavirus Research at FIU by an authorized administrator of FIU Digital Commons. For more information, please
contact dcc@fiu.edu.

Review

Immunopathol Persa. 2021;7(2):e30

Immunopathologia Persa

http www.immunopathol.com

DOI:10.34172/ipp.2021.30

Gut microbiota in COVID-19 treatment
ID

Tella Sadighpour1,2* , Audrey Tolouian3

ID

Florida International University, Herbert Wertheim College of Medicine, Miami, Florida, USA
American University of Antigua, College of Medicine, Antigua and Barbuda
3
The University of Texas at El Paso School of Nursing, El Paso, Texas, USA
1
2

*Correspondence to
Tella Sadighpour,
Email: Tella.90s@gmail.com,
tsadi003@fiu.edu,
tellas@auamed.net
Received 7 Apr. 2021
Accepted 14 May 2021
Published online 1 June 2021

Abstract
A novel coronavirus (severe acute respiratory syndrome coronavirus [SARS-CoV-2]), has been causing a
COVID-19 pandemic of acute respiratory syndrome in humans since December 2019. It appears to be similar in
structure to the virus that caused the SARS-CoV outbreak of 18 years ago. However, in addition to the respiratory
disorders, the COVID-19 patients might suffer extra-pulmonary disorders, including gut dysfunction or liver
dysfunction complications, which show as gut–lung crosstalk. Fecal specimens should be considered as a source
of detection of SARS-CoV-2 as one of the routine diagnostic tests in order to guide hospital’s liberation and release
of quarantine of patients.
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Introduction
The
gastrointestinal
and
respiratory
tracks both contain commensal bacteria.
Identification of those bacteria can be very
useful. The role of microbiota in a healthy
immune response is generally well accepted,
while gut dysbacteriosis might result in
chronic inflammatory lung diseases, hence
their identification could be indicative of
other diseases. Intervention to change the
gut microbiota may decrease disease severity.
Thereby, detecting the role of microbiome
in viral diseases, and developing the
novel therapeutic strategies to change the
microbiome by probiotics, personalized diet,
and traditional Chinese medicine to regulate
the immune system and restrain cytokine
storm is pivotal.
Materials and Methods
Articles related to this topic were searched in
PubMed, Scopus, Web of Science, Embase,
Directory of Open Access Journals (DOAJ)
and Google Scholar, using the following
keywords or their combinations; COVID-19,
SARS-CoV-2, ACE2 receptors, gastrointestinal
microbiota and gut microbiota.
Angiotensin-converting enzyme 2 receptors
Severe
acute
respiratory
syndrome
coronavirus (SARS-CoV-2) has been causing
the COVID-19 pandemic of acute respiratory

Key point
Recent research highlights the existence of a “gutlung” microbial axis and its impact on lung diseases.
Gut dysbiosis has a negative impact in response to
COVID-19 treatment, particularly in patients with
progressive lung disease.

syndrome in humans since December 2019.
It appears to be similar in structure to the
virus that caused the SARS-CoV outbreak of
18 years ago (1,2 ).
One study used molecular modeling to
show structural similarity between receptors
of the SARS-CoV and COVID-19, therefore
suggesting angiotensin-converting enzyme 2
(ACE2) as the receptor for COVID-19 (1, 3).
It is recognized that ACE2 is widely
distributed in the epithelia of the lungs and
small intestines, whereas lower expression
has been observed in the crypt cells and the
colon (2).
COVID-19, in addition to pulmonary
involvement, can cause liver and gut
dysfunction, suggestive of gut–lung crosstalk
(1). ACE2 receptors in human enterocytes
are digestion-related enzymes and act as a
conserved cell reservoir for coronaviruses.
Interestingly,
dipeptidyl
peptidase-4
(DPP4) and alanine aminopeptidase are
highly expressed in enterocytes in the small
intestines of mice and act as receptors for
other coronaviruses of MERS-CoV and
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HCoV-229E respectively (3). Zhang et al analyzed lung,
esophagus, gastric mucosa, ileum and colon data in
order to identify prime target cells of SARS-CoV-2 by
comprehensive dissection of ACE2 and trans-membrane
protease serine 2 (TMPRSS2) co-expression pattern.
Preventive health outcomes may be influenced by these
findings (4).
Digestive system
The descriptive, multi-centric study, with 204 COVID-19
patients, showed half the patients were reported to have
digestive symptoms such as anorexia, diarrhea, vomiting,
abdominal pain and higher liver enzymes. In rare cases,
there were patients with digestive and hepatic symptoms
without respiratory symptoms. Various hypotheses
have arisen to explain digestive and hepatic symptoms
in COVID-19. First, SARS-CoV-2 binds to ACE-2
receptors throughout the whole human body, inclusive
of the digestive and hepatic systems. Second, using an
inflammatory response, SARS-CoV-2 causes direct
and/or indirect damage to the digestive system. Third,
SARS-CoV-2 causes impairment of the gastrointestinal
microbiota in the human intestine (4).
There is evidence that SARS-CoV-2 infects mature
human enterocytes through TMPRSS2 and TMPRSS4
serine proteases by inducing cleavage of the S protein and
enhancing membrane fusion (5).
Recent evidence showed that 15–53% of the patients
with COVID-19 suffer mild to moderate liver injury
with elevated aminotransferases, hypoproteinemia, and
prothrombin time prolongation, with a frequent mild
rise in serum bilirubin. Although the mechanism of liver
injury is not completely understood, the liver injury can
be due to direct viral infection of hepatocytes, immunerelated injury, or drug hepatotoxicity (6,7). Moreover,
Chai et al showed the expression of ACE-2 receptors
in cholangiocytes, which causes liver abnormalities in
patients with COVID-19 (8).
Postmortem liver biopsy of individuals with COVID-19,
exhibited microvesicular steatosis and mild lobular
activity (9). The “gut-lung” microbial axis and its impact
on lung disease development, has been explored in recent
research. For example, it has been recently shown that
histamine secretions from the gut microbial are higher
in asthmatic patients versus healthy persons (10). It has
been suggested that “early-life” microbial exposure might
affect the immune response and subsequently cause lung
diseases (11).
Whether the virus gets to the digestive tract via
cellular divisions from the respiratory system or clones
in the digestive system is not clear. It is still practically
recommended to take primary steps to inhibit fecal–oral
transmission in public and in the hospital. The existence
of fecal-respiratory and fecal–oral transmission route in
patients with COVID-19 has been confirmed. Therefore,
a need for further clinical trials and using antiviral drugs
2
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directing digestive system is warranted (12).
Fecal transmission
Asymptomatic children and adults may be able to transmit
the SARS-CoV-2 virus particles to others through fecal
shedding. Fecal specimens should be considered as a
source of detection of SARS-CoV-2 as one of the routine
diagnostic tests (13).
The analysis of fecal microbiota is the most common
way to investigate gut microbiota (14). A pilot study
with 15 hospitalized patients with COVID-19 showed
continuous changes in the fecal microbiome versus the
control subjects, which were associated with the severity
of COVID-19 too (15). More studies need to expose
its reproduction ability, is transferability in stool and its
stability in the environment that would interrupt SARSCoV-2 as well to distribute it among human hosts.
Gut microbiota
Based on hygiene hypothesis, gut microbiota has been
known as one of the main factors of increasing incidence
of immunity-associated diseases. For example, metabolic
syndrome, allergic disorders, liver disorders, cardiovascular
diseases, neurodegenerative diseases, and cancer, could be
targeted and treated more efficiently by better recognizing
of gut microbiota in personalized healthcare (16). It is
proposed that manipulation of the gut microbiota can
prevent or decrease the intensification of lung diseases.
The role of gut dysbiosis in lung diseases comprising
allergy, asthma, chronic obstructive pulmonary disease,
cystic fibrosis and lung cancer, have been observed by
extensive studies (14,16,17).
Over the past years, studies with poliovirus, norovirus,
mouse mammary tumor virus and influenza virus have
shown the connections between the microbiota and virus
infections (18). Numerous investigations have found that
when the gut microbiota is harmonized, it can decrease
inflammation of the small intestine and ventilatorassociated pneumonia and in addition, it has been noted
that this can also reduce side effects of antibiotics against
influenza virus replication (19).
The microbiota may have direct or indirect effects on
viral infection (17). Microbiota is able to change the host
immune systems and regulate the responses to various
viral pathogens (20).
The variety of intestinal microbiota and the existence
of advantageous microorganisms in the intestinal tract
could play a vital role in prevention, treatment and also the
duration of COVID-19 disease (21). A potential target to
fight against SARS-CoV-2 could be to decrease intestinal
ACE2 expression by some specific gut microorganisms.
In fighting COVID-19, enhancing the immune system
by modulating the gut microbiome should be considered
as a therapeutic option. One way for advancing a healthy
microbiome may involve procedures to increase intestinal
butyrate production and decrease pro-inflammatory
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conditions via nutritional alterations (22).
It is interesting to study whether variations of gut and/
or lung microbiota may modulate the reaction of ACE2
on enteric viruses. However, gut microbiota enhances
antiviral immunity by increasing the number and
function of immune cells, reducing immunopathology,
and inducing interferon production (23). The effects of
commensal bacteria to facilitate the viral attachment to
the host enteric cells and ensue infection have been shown.
Any intervention in microbiota-virus interactions may be
considered as a new, therapeutic methods in preventing
the disease (24).
A study by Herbst et al confirmed that airway
inflammation and hypersensitivity induced by ovalbumin
is much weaker in specific pathogen-free environment mice
that were colonized with commensal microbes compared
to germ-free mice (25,26). The recognition of commensal
bacteria in both respiratory tracts and the gastro-enteric
region might be an important and inventive subject.
The role of microbiota in a healthy immune response is
generally well accepted, while gut dysbacteriosis might
result in chronic inflammatory lung diseases.
The dysbiosis gut activates inflammatory pathways
and leads to bronchoconstriction and bronchial
hyperresponsiveness.
The
phyla
Bacteroidetes,
Actinobacteria, and Firmicutes are prevalent in the healthy
gut and lung microbial composition. The abundance of
Proteobacteria with genera Haemophilus and Moraxella
have been observed in persons with lung disorders (27).
The gut-lung crosstalk effects of gut microbiota are partly
associated with producing metabolites, including short
chain fatty acids, which could repress lung inflammation
through the activation of serpentine receptors (28).
Melatonin and sodium butyrate are actively inhibited by
most viruses. Benefits of melatonin and sodium butyrate
in the management of COVID-19 emerge from induction
of the melatonergic pathway and their ability to decrease
the gut permeability (29). Stress also causes variations in
gut microbiome, gut permeability, circadian rhythm and
mitochondria, which look to be similar to the changes,
induced by viruses; including a decrease in both melatonin
and butyrate, thereby symbiosis in immune system and
increase infection severity (30,31).
Some drugs, such as antibiotics and antiulcer
medications, weaken gut and lung microbiota. The
effective factors in intestinal dysbiosis are summarized in
a review by Weiss et al. Natural variations induced by the
changing supply of nutrients; drugs, the immune system,
and the intestinal mucosa contribute to gut dysbiosis. The
processes of stress factors, such as oxidative stress, the
induction of bacteriophages, and secretion of bacteriocins
changes microbial composition and cause reduced variety
and growth of specific bacterial taxonomy (32).
Gut dysbiosis and COVID-19
In the hospital setting, gut dysbiosis may cause negative

impact in response to COVID-19 treatment, particularly
in patients with progressive lung disease. Therefore, the
preventive or protective approaches of intestinal dysbiosis
should be considered when combating with COVID-19
(32).
Zuo et al showed that persistent fecal microbiome
alteration, is associated with fecal shedding of the virus
and severity of COVID-19 (33).
Numerous small case reports from China showed
reduced Lactobacillus and Bifidobacterium in some
COVID-19 patients. Therefore, dietary modification with
prebiotics and probiotics has been proposed (33).
A cohort study with 57 patients, investigated changes in
the abundance of ten kinds of main gut bacterial groups
in COVID-19 patients, using quantitative polymerase
chain reaction (q-PCR), and explored the relationship
of these groups with the severity of COVID-19 (general,
severe, or critical). The results of this study showed that
dysbiosis arisen in COVID-19 individuals since alterations
in the gut microbial flora were related to disease intensity.
Conversely, the abundance of butyrate-producing bacteria
also significantly decreased the severity of the disease (34).
Nutrients and microbes
The gut in healthy humans includes more than 1000
bacterial species (35). According to previous discussions
and improvement in our perception regarding the role
of the microbiome in virus illness, the new therapeutic
modalities to modify the microbiome through probiotics,
personalized diet, and traditional Chinese medicine may
help to regulate the immune system and restrain cytokine
storm (36). A narrative review assesses scientific studies
published from 2005 to 2019 and evaluated the effect
of micro- and macro-nutrients including tea-derived
polyphenols, dietary fibers, vitamins, supplementation
of calcium, magnesium, phosphorus, selenium, zinc,
quantity and type of fat and proteins on the constitution of
the intestinal microbiome by in vitro and in vivo models,
and the clinical trials by human studies. It was found that
these nutrients have a beneficial effect on good flora and
help to suppress harmful flora (37).
Plant/Western dietary patterns
Many investigators have reported relationships between
numerous lifestyle parameters and lung diseases. Dietary
patterns are associated with prevalence, incidence,
pulmonary function, and exacerbation of lung diseases.
The intake of raw vegetables is particularly important
among healthy diets. However, a large amount of evidence
supports the concept that plant-based diets and raw
vegetable diets in particular, have beneficial effects on lung
disease. It has been found that traditional dietary patterns
were associated with higher proportions of Bacteroides
(Bacteroidaceae) and Bifidobacterium (Bifidobacteriaceae,
Actinobacteria) and a lower proportion of Prevotella
(Prevotellaceae) relative to modified Western dietary
Immunopathologia Persa Volume 7, Issue 2, 2021
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patterns (38). Fermentation of dietary fibers by the
gut microbiota produced short chain fatty acids, such
as butyrate, which inhibits pulmonary type 2 innate
lymphoid cells functions and subsequent development of
airway hyper-reactivity (37).
Probiotics
Probiotics are living organisms that are beneficial for
health when consumed in adequate amounts; both in the
form of diet and drugs. The antiviral activity of Plantiricin
compounds, via binding with RNA dependent RNA
polymerase, residual binding domain, and ACE2 has been
illustrated (39).
The therapeutic potential of using pro‐ and prebiotics
to prevent or reduce the risk of COVID-19 exacerbations
is one important issue. Probiotics may modulate the gut
microbiota to alter the gastrointestinal symptoms and may
also protect the respiratory system. With China’s guidance
in early February, it was suggested that probiotics can be
used to adjust gut micro- ecology and help to prevent
secondary bacterial infections in patients with severe
COVID-19 infections (1).
It is known that prebiotics such as wheat, bran, fructooligosaccharides (Fos), and galactosaccharides (Gos)
increase butyrate levels, reduce inflammation and improve
lung diseases (40). These probiotics may modulate
the immune system. Experimental investigations have
shown that introduction of probiotic bacteria such as
Lactobacillus rhamnosus, Bifidobacterium lactis and
Bifidobacterium breve, can reduce allergic response (41).
Lung metagenomic studies on patients with COVID-19,
revealed Prevotella proteins are involved in multiple
interactions with NF-kB, which causing clinical severity
of COVID-19 infection (42). A review of 11 randomized
clinical trials containing a total of 2417 children who
received probiotics showed the reduction of respiratory
infection (43). One initial study suggested that prebiotic
and probiotic use improved pulmonary function
parameters and reduced the systemic production of Th2
cytokines in allergic asthmatics (44). Another study using
a nutritional combination of a probiotic with fish oils and
vegetable extracts which caused significant improvement
in children with asthma and reduced the need for inhaled
bronchodilators and corticosteroids, proposing that a
combination of numerous methods may result in the best
outcomes (45).
Possible mechanisms by which probiotic bacteria may
exert antiviral activity are as follows: direct interaction
to the virus as an adsorptive or trapping mechanism,
stimulation of the immune system by interleukin, natural
killer cells, Th1 immune response activity, IgA production
and production of antiviral agents such as hydrogen
peroxide, lactic acid, and bacteriocins (16,46). Two metaanalysis reported moderate efficacy of probiotics in
reducing the prevalence and the course of respiratory tract
infections with viral origin (47,48).
4
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In an open-label, randomized-controlled multicenter
trial, 235 severely ill adult patients on mechanical
ventilation, were received probiotics (Bacillus subtilis
and Enterococcus faecalis) versus placebo. The probiotics
were shown to prevent significantly ventilator-associated
pneumonia versus the control. The fundamental
mechanism includes inhibition of the colonization of
potentially pathogenic microorganisms in the gut by
probiotics (49).
In China, 58%–71% of COVID-19 patients were
delivered antibiotics, 2–36% of patients suffered diarrhea.
However, there is conflicting evidence here, for example,
while a 2012 meta-analysis (50) showed that probiotics
reduced antibiotic associated diarrhea modestly.
Additionally, a large randomized, placebo-controlled trial
with 2941 patients (51) showed that combined probiotics
of Lactobacilli and Bifidobacteria during 21-days did not
decrease antibiotic-associated diarrhea.
Interventions to change the gut microbiota may
decrease disease severity. The use of antibiotics may cause
more damage to the healthy commensal microbiome
and intensify gut dysbiosis in COVID-19 patients. It
is suggested that avoiding of unnecessary antibiotic
administration in the treatment of viral lung diseases can
preserve the beneficial bacteria in the gut boundary (15).
It has also been reported that the expression of
coronavirus receptors did not reduce when probiotics,
such as segmented Filamentous bacteria, Lactobacillus
acidophilus and Bacillus clausii were used (3). Therefore,
the probiotic effect on gut microbiota and the pathogenesis
of SARS-CoV-2 needs more research and irrational use of
common probiotics for COVID-19 is not suggested (52).
In Europe, products other than probiotics are available
as oral health products and have been tested in clinical
practice. The use of a mouth rinses and/or nasal
applications that contain cyclodextrins combined with
Citrox could lower the SARS-CoV-2 viral load and reduce
the nasopharyngeal microbiota, as they tend to coat the
surface aerosol particles and droplets during coughing or
sneezing. Clinical trials to assess the inhibitive effects of
cyclodextrins - Citrox therapeutic oral biofilm rinses in
the reduction of the viral load of the infection and disease
progression is necessary (53).
Conclusion
Recent research highlights the existence of a “gut-lung”
microbial axis and its impact on lung diseases. Gut dysbiosis
has a negative impact in response to COVID-19 treatment,
particularly in patients with progressive lung disease.
The preventive or protective approaches of intestinal
dysbiosis should be considered in combating COVID-19.
Progressing our understanding about the function of the
intestinal microbiome in viral illnesses, new therapeutic
modalities, regarding the modifying of microbiome by
probiotics, personalized diet, and traditional Chinese
medicine to regulate the immune system and restrain
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cytokine storm, can improve the outcome of COVID-19.
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